Home › Brain Tumors › NCT00870129
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Using Advanced MR Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans: A Pilot Study, and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Suspected or Histopathologically proven diagnosis of high grade or low glioma or tumor is suspected to harbor an isocitrate dehydrogenase (IDH) mutation * May undergo radiation therapy * Patient and/or guardian is able to provide written informed consent prior to study registration * Age ≥ 18 years old Exclusion Criteria: * Extreme claustrophobia that precludes MRI scan * Known allergic reaction to Gd-DTPA * Any contraindication to gadolinium intravenous contrast as per standard Department of Radiology contrast guidelines * Any absolute contraindication to MRI (e.g., pacemaker, aneurysm clip, tissue expander). * Pregnant or nursing female * Unable to cooperate for MRI and/or radiation therapy planning
About the study
The researchers think that the use of advanced MR imaging may help people with this disease, because it may better predict areas within a malignant glioma (brain tumor) that are at a high risk of recurring. WeThe reserchers are doing this study to see whether this advanced imaging is a safe treatment that causes few or mild side effects in people with brain tumors.
What is being tested
- MRI and advanced MRI sequences (procedure)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 135 · Started: 2009-03
Contact the study team
- Robert Young, MD · Phone: 212-639-8196
- Sunitha Thakur, PhD · Phone: 646-608-8262
Official record on ClinicalTrials.gov — NCT00870129
Locations in the U.S.
| New York | Memorial Sloan Kettering Cancer Center, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.